Commonly called Strep zoo. Know the risks, recognize the signs and find reliable information for chinchilla care.
Educational information, not an individual diagnosis or treatment plan.
Updated October 28, 2026
Why this disease deserves its own page.
Streptococcus equi subsp. zooepidemicus, often called Strep zoo, is an increasingly recognized concern in chinchilla care. The Merck Veterinary Manual describes it as increasingly diagnosed in chinchillas. GCA has dedicated this page to helping families recognize warning signs, seek timely veterinary care and find reliable information in one place.
Watch for new lumps or abscesses around the neck or under the jaw, and inflamed eyes with discharge. Any swelling or suspected abscess in the groin or elsewhere, or eyes swollen or crusted shut, also needs prompt veterinary attention, whether caused by Strep zoo or another condition. Reduced appetite, weight loss, lethargy or breathing changes are additional reasons to contact a veterinarian without delay.
These warning signs are not specific to this infection. Published reports do not establish how common it is across all pet chinchillas, and some infected animals show no outward signs. Veterinary examination and laboratory testing are essential.
FROM CHINCHILLA CONNECTION
Read the magazine features.
Case observations, testing discussions and outbreak experiences from GCA’s magazine. Select an article to read all its pages, or open an individual page below.
Read with the corrections: Do not use creosote on chinchilla housing. The archived chemical ratios and fixed quarantine period are not universal instructions. The full article opens with the current corrections.
Call before visitingDescribe symptoms, recent arrivals and known exposures. Ask how to transport and present the animal safely.
Limit opportunities to spreadPending veterinary advice, keep affected animals apart from unexposed animals and pause transfers of potentially exposed animals.
Separate care equipmentAvoid sharing cages, carriers, bowls, dust baths and cleaning tools between affected and unaffected groups. Wash hands between groups.
Make a veterinary planAsk about testing, protective equipment, cleaning, monitoring other animals and criteria for ending isolation.
Respiratory secretions, close contact and contaminated equipment can spread the organism. Your veterinarian should tailor precautions to your species and facility. Clean and disinfect according to that plan and product instructions.
Do not copy antibiotic advice for another species.
Medication choice, route and dosing must come from a veterinarian familiar with chinchillas. Do not use leftover antibiotics or attempt to drain an abscess yourself. A calendar-based quarantine alone is not proof that an animal is free of infection.
Bring useful information.
Keep a dated record of signs, appetite, weight changes, arrivals, animal contacts and laboratory results. Ask your veterinarian whether the laboratory can retain an isolate if further investigation is needed.
WHAT THE RESEARCH SHOWS
What it can mean for chinchillas.
A 2020 research-colony report described abscesses, mild weight loss and respiratory disease. Six of 43 chinchillas tested positive by culture or PCR; some positive animals had no clinical signs. Those numbers describe that colony, not prevalence in pet chinchillas nationally.
A normal appearance does not rule out infection. A veterinarian must interpret signs, exposure history and appropriate testing together. Culture and PCR were used in the published investigation.
Streptococcus equi subsp. zooepidemicus is distinct from Streptococcus equi subsp. equi, the usual cause of equine strangles. Ask for the exact laboratory identification.
Testing needs context
Ask your veterinarian to arrange appropriate sampling, bacterial culture and identification to the subspecies level, rather than stopping at a result of “Streptococcus species.” The laboratory may use additional testing, such as PCR, to distinguish S. equi subsp. zooepidemicus from S. equi subsp. equi. Discuss antibiotic susceptibility testing to guide treatment. Subspecies identification is different from strain typing, which may be useful in an outbreak investigation.
Published chinchilla cases, isolate-specific susceptibility results and documented outcomes. The evidence below distinguishes laboratory susceptibility, clinical improvement and demonstrated resolution.
Reported treatments & outcomes
Chinchilla-specific reports of treatment for Streptococcus equi subsp. zooepidemicus (SEZ). Published cases and ranch records / caretaker observations are identified separately; improvement does not necessarily establish elimination of infection.
Chinchillas cannot safely receive every antibiotic. Disruption of intestinal flora can cause severe enteritis or enterotoxemia; loss of appetite and reduced fecal output also raise concern for gastrointestinal hypomotility or stasis. Penicillins, cephalosporins, clindamycin, lincomycin and erythromycin require particular caution. Drug, formulation and route matter: a susceptible laboratory result does not establish safety in a chinchilla, and an injectable treatment must not be substituted with an oral preparation. Chinchilla pathology reference.
Treatment
Route & reported course
Reported result
Evidence & limits
Trimethoprim–sulfamethoxazole SMZ-TMP / TMP-SMX
Oral. Dose and duration not verified in the accessible abstract.
Resolution reported in a four-month-old pet chinchilla with a culture-confirmed cervical abscess.
Published single case: Berg, Doss & Mans, 2019. This supports a reported success, not a universal regimen.
SMZ-TMP Reported by ranch records / caretaker
Oral, twice daily for a minimum of 10 days, as reported by the caretaker; longer courses of around 30 days or more have also been used.
Caretaker reports the best observed response and appetite tolerance among treatments used.
Caretaker account, October 2026; no matched patient series or clearance results supplied for these courses. A 30-day course is not established here as an eradication protocol.
SMZ-Med 454 Sodium sulfamethazine alone
In drinking water for 14 days, alongside eye treatment reported as “Vetromycin Plus.”
32 of 40 chinchillas (80%) showed no symptoms after treatment, according to the caretaker. Both water medication and eye treatment were used.
Caretaker report, October 2026. Symptom resolution was observed; microbiological clearance and follow-up duration were not documented. The combined treatments do not establish the effect of either product alone. Product identity.
Gentamicin Sometimes with local abscess or eye treatment
Five-day injectable courses in ranch records; SC documented in 2021 logs.
Mixed outcomes. J46 is reported by the caretaker to have remained Strep-free since the five-day gentamicin course in May 2021. K316 had early improvement in eye discharge, then developed a neck abscess and was euthanized.
May 2021 treatment logs with SEZ confirmation; concurrent treatments prevent attributing response to gentamicin alone. J46’s long-term outcome is caretaker-reported; follow-up laboratory confirmation of clearance has not been provided. Case records. Renal toxicity is a major concern.
Penicillin Reported by ranch records / caretaker
IM (intramuscular), confirmed by the caretaker. Exact product, dose and course not yet linked to a patient record.
Use reported; a specific outcome has not been established from the matched records.
Included as treatment history, not a proven success. The older written SOP describes a separate SC protocol; it does not change the caretaker’s account of IM use.
Abscessed lymph-node excision + enrofloxacin
Published course: enrofloxacin 10 mg/kg orally twice daily for 14 days, with analgesia.
External healing, persistent internal disease. Another abscessed lymph node was found at necropsy four weeks later.
Single research chinchilla; 2022 AALAS abstract P104. The reported dose describes that case; it is not evidence of reliable clearance.
These are reported courses, not interchangeable prescriptions. Individual selection and duration depend on the isolate, infection site, patient status and veterinary assessment. Laboratory susceptibility alone is not a clinical treatment outcome.
Medication tolerance & additional historical reportsGut health, kidney risk, water medication and the older penicillin protocol.
Appetite and gut health: SMZ-TMP’s favorable tolerance reported by the caretaker is an observation, not proof that it is risk-free or superior in all chinchillas. Reduced eating or fecal output during any course warrants prompt veterinary reassessment.
Gentamicin and kidneys: Adequate hydration matters, but drinking plenty of water does not eliminate nephrotoxicity. Renal function, hydration, total exposure and other nephrotoxic drugs need consideration. Aminoglycoside safety reference.
Injectable penicillin evidence: A 2026 retrospective study included 43 chinchillas receiving penicillin G procaine/benzathine and 24 receiving ceftiofur. Administration was SC in every case; two penicillin-treated chinchillas had suspected adverse effects, with no gastrointestinal clinical signs reported as adverse effects. This is useful tolerance evidence, but does not validate IM use, oral use or effectiveness against SEZ. Cooper & Mans, 2026.
Sulfamethazine in water: A five-day tolerance study in 12 chinchillas reported no adverse general-health, fecal-quality or body-weight changes, but water consumption declined, particularly at the higher concentration. It did not test SEZ treatment efficacy or a 14- or 30-day course. Water intake affects delivered dose. Šakar et al., 2005.
Historical treatment presentation: A 2015 presentation retained in ranch correspondence described SC gentamicin, gentamicin eye drops and, for persistent disease, combination treatment followed by long-acting penicillin over about a month. Its presenter reported no improvement with oral SMZ-TMP in their animals. These are third-party observations, not a controlled study or verified ranch outcomes. The month-long protocol in that presentation concerns penicillin; it does not establish a 30-day SMZ-TMP clearance rule.
Common antibiotics: chinchilla tolerance
This general reference covers antibiotics used for different chinchilla infections. Tolerability does not establish effectiveness against Strep zoo. “Generally tolerated” means recognized veterinary use, not a guarantee that an individual animal will tolerate treatment.
Medication
General tolerance / use
Important cautions
Trimethoprim–sulfonamide Includes SMZ-TMP
Generally well tolerated. Caretaker experience reports maintained appetite with SMZ-TMP; individual tolerance still varies.
Not appropriate with pre-existing renal insufficiency in the cited guidance. Appetite and fecal output still require monitoring. UZH guidance.
Doxycycline
Generally well tolerated when appropriately prescribed, including oral use. Continued normal feeding should be monitored; appetite loss remains possible.
Calcium can interfere with absorption. The veterinarian should review administration and supplement timing; this is not a reason to withhold hay. UZH guidance.
Enrofloxacin (Baytril) / marbofloxacin
Generally tolerated options when the organism is susceptible.
Appetite loss during treatment warrants reassessment. Caretaker reports frequent appetite loss with oral enrofloxacin; the cited chinchilla guidance describes these drugs as generally tolerated and does not establish that most animals stop eating. Injections can cause pain and local tissue injury. UZH guidance.
Chloramphenicol
Recognized option, including oral use.
Human handling hazard: use gloves and follow dispensing instructions because exposure can cause serious blood disorders. UZH guidance.
Metronidazole
Use with particular caution; may be considered for selected anaerobic infections.
Can cause anorexia in chinchillas. The cited guidance reserves it for circumstances without suitable alternatives. UZH guidance.
Gentamicin / amikacin Systemic aminoglycosides
Require particular renal-risk assessment and monitoring.
Potential kidney toxicity. Hydration is important but does not eliminate risk. Systemic injections and ophthalmic preparations are different exposures. Aminoglycoside reference; chinchilla guidance.
High concern for antibiotic-associated intestinal disease. Oral preparations are not routine substitutes for the injectable regimens reported here.
These drug families are identified in chinchilla antibiotic-toxicity warnings. An “S” on a susceptibility report does not override species and route concerns. Pathology reference. See the specific injectable evidence below.
Injectable penicillin G procaine/benzathine & ceftiofur
Specific formulations have published chinchilla tolerability data under veterinary care.
The 2026 retrospective study used SC administration. Its findings do not establish safety for all formulations, IM administration or oral use, and do not prove SEZ efficacy. Cooper & Mans.
Clindamycin, lincomycin & erythromycin
Generally avoided because of serious gut-flora disruption and enterotoxemia risk.
Do not extrapolate routine dog/cat prescribing or laboratory susceptibility to chinchilla safety. Pathology reference.
A small five-day study does not establish long-course safety. Reduced water intake can alter the dose received; the ranch’s 14-day outcome is documented separately above. Šakar et al..
Appetite loss and assisted feeding: Caretaker experience includes loss of appetite with oral enrofloxacin and some other oral antibiotics, sometimes requiring assisted feeding. This is a reported observation, not a measured rate across chinchillas. If eating declines, contact the veterinarian promptly to assess the medication, underlying disease, hydration and gut function. Veterinarian-directed assisted feeding may be needed; force-feeding is not an automatic response, particularly if obstruction or unsafe swallowing is suspected.
Watch the animal, not just the infection: reduced eating, fewer or smaller fecal pellets, diarrhea, abdominal distension or marked lethargy during treatment require prompt veterinary reassessment. Intestinal dysbiosis, enterotoxemia and GI stasis are related concerns but are not interchangeable diagnoses. When GI function is abnormal, oral drug absorption and effectiveness may also be impaired. Merck Veterinary Manual.
Route and formulation matter for eye medications too: an ophthalmic product is not interchangeable with a skin/wound product or a systemic injection. Local eye treatment does not establish clearance of infection elsewhere in the body. Chinchilla ocular-treatment guidance.
There is no established, universally effective chinchilla Strep zoo regimen in the reviewed evidence. Published experience is limited. A medicine can test susceptible in the laboratory yet fail to eliminate an abscess or carrier state. A susceptible result also does not establish that the drug, formulation or route is safe for chinchillas.
Evidence
Treatment or finding
Outcome and limitation
Pet chinchilla, 2019 Single case report
Cervical abscess; aerobic culture and MALDI-TOF identified SEZ. Oral trimethoprim–sulfamethoxazole was reported.
The abstract reports resolution. Exact dose, duration and follow-up have not been verified from the full paper, so they are not supplied here. Berg, Doss & Mans.
Research chinchilla, 2022 Conference poster abstract P104; one animal
Lymph-node removal plus enrofloxacin 10 mg/kg orally twice daily for 14 days; meloxicam also used. This is the reported case regimen, not a recommendation.
The animal reached its four-week research endpoint and the surgical site healed, but enlarged regional lymph nodes and abscesses were found at necropsy. Short-term management did not demonstrate eradication. AALAS abstract P104.
Chinchilla colony, 2020 Outbreak investigation
One abscess isolate was susceptible in vitro to several agents, including trimethoprim–sulfamethoxazole, enrofloxacin, tetracycline and chloramphenicol.
This was not a treatment trial. Euthanasia reflected research and biosafety decisions; it does not demonstrate antibiotic failure. Susceptibility was measured for one isolate. Mitchell et al.
Other-species case evidence — context for veterinarians
A cat with culture-confirmed SEZ meningitis and otitis received initial parenteral antibiotics, bulla surgery and prolonged oral trimethoprim–sulfamethoxazole, with a normal neurological examination at eight months. This is evidence from one cat, with several simultaneous interventions; it does not establish a chinchilla regimen. Martin-Vaquero et al., 2011.
Dog/cat shelter outbreak guidance includes population-level antimicrobial decisions. Those recommendations require species-specific veterinary interpretation before use in a chinchilla facility. ASPCApro.
The Ryerson-sourced research colony · Mitchell et al., 2020Cases from 2017–2018 · abscesses, septic pleural effusion and susceptibility findings.
Mitchell and colleagues’ Diagnosis, Surveillance and Management of Streptococcus equi subspecies zooepidemicus Infections in Chinchillas was published in August 2020 and describes clinical cases and surveillance from 2017–2018. Its husbandry section identifies Ryerson Chinchilla Ranch, Plymouth, Ohio, as the supplier.
Clinical findings: cervical and axillary abscesses, mild weight loss and, in a later animal, respiratory depression with culture-confirmed septic pleural effusion. Fur obscured one large abscess during routine visual observation.
Detection: six of 43 animals were positive by culture or PCR; two positive animals had no clinical signs. These figures describe this research colony, not pet-chinchilla prevalence.
Susceptibility: Kirby–Bauer testing of the second clinical case’s isolate reported susceptibility to amikacin, amoxicillin/clavulanic acid, azithromycin, cefazolin, ceftiofur, chloramphenicol, enrofloxacin, erythromycin, gentamicin, trimethoprim–sulfamethoxazole, tetracycline and tulathromycin. These results do not establish chinchilla safety for every drug or route, or treatment success.
Outcome: affected research animals were euthanized; this was not an antibiotic-treatment trial.
The authors considered infection before arrival likely, but described that origin as speculation. Supplier identification is historical context, not evidence of the supplier’s present-day health status.
Two final necropsies document severe pneumonia with Strep zoo isolated in animals whose submitted histories described normal behavior or no observed warning signs. Abscess cultures and PCR records add further diagnostic evidence. Each case below includes a summary and the original redacted laboratory PDF.
Names, addresses and personal contact details have been removed from report copies. Laboratory findings and interpretive comments are preserved. These are individual cases, not proof of a treatment’s effectiveness.
Sudden death & pneumonia2 final necropsies · 2025 and 2026 · read the findings and original reports.
Confirmed pathology • February–March 2026
Sudden death despite no observed warning signs
A seven-month-old female chinchilla was found dead in her enclosure. The submitted history recorded no prior clinical signs and blood at the nose and mouth; necropsy documented good body condition. The final diagnosis was marked right-sided necrotizing bronchopneumonia, marked fibrinosuppurative pleuritis and mild fibrinous epicarditis. SEZ was recovered from lung, liver and right pleural swabs. Numerous Gram-positive cocci were present in affected lung.
The report describes red opaque fluid in the right chest cavity and blood staining externally. It does not use “hemorrhagic pneumonia” as its final diagnostic label. No antibiotic susceptibility panel is included. This case demonstrates that severe internal disease can coexist with a history of normal outward appearance; it cannot establish how frequently this occurs.
The submitted history describes a male chinchilla eating and behaving normally before being found dead with blood around the mouth. The final report documents severe unilateral necrotizing and suppurative pneumonia, pulmonary and perivascular edema, vasculitis and intralesional bacteria. SEZ was isolated from lung and liver. Necropsy recorded good nutritional condition and red-tinged thoracic fluid.
Source discrepancy: the specimen table says 16 months, while the clinical history says two years. Both are preserved in the original; age should be reconciled before using this case in a formal case series. No AST panel or treatment outcome is included.
Abscess cultures, susceptibility & PCR4 reports · confirmed Strep zoo, two susceptibility panels and a discordant result.
Culture plus reported susceptibility • May–June 2021
Two separate abscess isolates with susceptibility results
Cases 244 and 287 each yielded SEZ at 2+ growth from abscess specimens collected on 29 May 2021. Both final reports list “S” for penicillin, amoxicillin, amoxicillin/clavulanic acid, cephalexin, erythromycin, doxycycline, chloramphenicol and trimethoprim-sulfa. No numerical MIC values are provided. No organisms were isolated anaerobically.
These are laboratory-reported categories, not a list of medicines safe to administer to chinchillas. The reports do not document administered treatment, clinical cure, relapse or eradication. Ask the laboratory about the testing method and interpretive basis if these historical results are being used in a clinical discussion.
J46: positive abscess culture and negative PCR report
The IDEXX final abscess report identifies SEZ at 1+ growth from a specimen collected on 11 May 2021. A separate Zoologix report received the same day lists two swabs for J46 as negative on assay B0019. Historical correspondence describes paired testing, but the two PDFs alone do not establish identical specimen material or explain the discrepancy.
The IDEXX report contains general antibiotic guidance and a susceptibility interpretation key, but no isolate-specific susceptibility table or numerical MIC results. Historical comments should not be treated as a current prescribing protocol. The laboratory correspondence raised possible target/strain mismatch; no sequencing confirmation was identified in the reviewed material.
The same original PCR report lists K316 positive for Streptococcus zooepidemicus; F298 is reported negative. The report identifies the submitted material only as swabs. Eye involvement is described in correspondence and must be attributed to that history, not silently inserted into the laboratory specimen field. An eye-specific culture/AST report has not yet been recovered.
The PCR document contains repeated rows on page 2; do not count these as additional animals. A batch result is not a population prevalence estimate or a guarantee that every negative animal is infection-free.
Treatment histories & outcomesK316 and J46 · caretaker records with laboratory confirmation and follow-up limits.
K316: improvement did not establish cure
The log records a five-day injectable gentamicin course beginning May 14, topical tobramycin beginning May 15, and a switch to gentamicin eye drops on May 25. A May 23 entry describes little or no pus, but the eye remained swollen shut. On May 30, the log records a large rupturing neck abscess and euthanasia. The PCR report independently confirms a positive result for K316. The record does not establish bacterial eradication, antimicrobial resistance, or which intervention caused a particular outcome.
J46: caretaker reports Strep-free since May 2021
The log records veterinary lancing and cleaning of a neck abscess on May 8 and a five-day gentamicin course beginning May 14. The final culture independently confirms SEZ. A later negative home agar plate and return to a blocked run are recorded. In an October 2026 update, the caretaker reports that J46 has remained Strep-free since the five-day gentamicin course in May 2021. This long-term outcome is caretaker-reported; follow-up laboratory confirmation of clearance has not been provided. Home agar results alone do not establish microbiological clearance.
A SHARED HEALTH CONCERN
Other animals and people can be affected.
Published reports include horses, guinea pigs, dogs, cats and other species. The organism can occur in horses without illness, yet cause serious disease in other settings. Finding it in one species does not prove it has spread to every animal nearby.
Dog outbreaks can cause rapidly progressive respiratory disease. Cats can develop respiratory or neurological illness. Evidence from dogs or cats must not be treated as a chinchilla treatment protocol.
Animal-to-human infection is documented, although human cases are uncommon. A study published by CDC examined serious human infections associated with horse contact. This establishes a zoonotic risk, not the likelihood of infection from any particular pet.
If you become unwell after contact with a suspected or confirmed infected animal, seek medical advice and mention the animal exposure and organism. Severe symptoms, including breathing difficulty, confusion or rapid deterioration, need urgent medical attention.
GCA is taking initial steps toward exploring vaccine development for Strep zoo in chinchillas. This is early-stage work. GCA is not announcing an available vaccine, a proven protective effect or a release date.
We will share specific milestones, confirmed collaborators and supporting evidence as that work develops. Vaccine research does not replace veterinary care and infection-control measures now.
ASPCA’s current shelter guidance states that no vaccine is available for prevention of Strep zoo. Vaccines intended for other organisms or species should not be assumed to protect chinchillas.
New research & what it meansEquine vaccine research, genomics and antimicrobial susceptibility; limits for chinchilla care.
A 2026 Finnish equine study adds a useful caution about interpreting AST. In its clinical-isolate table, 494/522 isolates were susceptible to trimethoprim–sulfamethoxazole, while 97/403 were categorized susceptible to tetracycline. The authors question the applicability of human-derived breakpoints and discuss reduced intrinsic tetracycline susceptibility. These are equine laboratory findings, not chinchilla treatment success rates. Junkkari et al., 2026, Table 2 and discussion.
A 2026 pony study evaluated a multicomponent vaccine during a natural respiratory outbreak and found fewer coughing days in vaccinated ponies. It does not demonstrate safety, effectiveness or availability of a chinchilla vaccine. Paillot et al., 2026.
A genomic study published in October 2026 examined 428 SEZ genomes, predominantly from horses, and identified genetic diversity and antimicrobial-resistance genes. Genomic findings do not substitute for susceptibility testing of a chinchilla’s isolate. He et al., 2026.
Important unresolved questions include chinchilla population prevalence, how well particular screening assays detect different strains, optimal treatment duration, persistence after apparent recovery, and validated criteria for release from isolation. Exploratory vaccine work must be described separately from a proven or available preventive treatment.
Mitchell et al. · Ryerson-sourced chinchillas · 2020
The University of Colorado colony investigation describing 2017–2018 cases. Includes abscesses, septic pleural effusion, asymptomatic positives and isolate susceptibility testing.
